SEC Form 4 · accession 0001209191-19-003409
IRONWOOD PHARMACEUTICALS INC · IRWD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Mallon
Officer — Executive Senior Advisor
Period of report
Jan 9, 2019
Accepted (ET)
Jan 11, 2019 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001446847
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Jan 9, 2019 | A | 93,036 | $0.00 | A | 93,036 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $12.32 | Jan 9, 2019 | A | 171,526 | A | — | Jan 9, 2029 | Class A Common Stock | 171,526 | 171,526 | D |
Explanation of responses
- F1The restricted stock unit award, granted as a new hire award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
- F2The option, granted as a new hire award, vests as to 25% of the shares of Class A Common Stock on the first anniversary of January 4, 2019 and 1/48th of the shares of Class A Common Stock vest each month thereafter for the next 36 months.